Pharmacy Compounding Accreditation Consulting — PCAB, USP 795, 797 & 800 | Integral Healthcare Solutions
Last updated: October 2026
IHS provides specialized accreditation consulting for compounding pharmacies navigating PCAB accreditation and the revised USP Chapters 795, 797, and 800 — all three of which achieved final enforceable status on November 1, 2023. We cover the full compliance lifecycle: gap assessment, SOP development, mock survey, on-site inspection support, and post-survey remediation. Thomas G. Goddard, JD, PhD, is the firm's principal.
What Is PCAB Accreditation?
PCAB (Pharmacy Compounding Accreditation Board) is an accreditation credential for compounding pharmacies in the United States. Administered as a service of ACHC (Accreditation Commission for Health Care) since PCAB's founding by a coalition of eight national pharmacy organizations in 2007, PCAB accreditation signals that a compounding pharmacy has demonstrated rigorous adherence to USP Chapter 795, 797, and 800 requirements through independent third-party review.
In the Alliance for Pharmacy Compounding's 2023–2024 survey (APC 2023–2024 Demographic Survey, opened October 3, 2026), 21% of pharmacies for which compounding is more than 20 percent of the business reported PCAB accreditation, and 16% said they plan to pursue accreditation within five years.
Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure.
Who Needs PCAB Accreditation?
Six categories of organizations pursue PCAB accreditation or USP compliance consulting:
- Dedicated 503A compounding pharmacies — independent, single-location, pursuing PCAB for state licensure, physician referral access, and payer credentialing
- 503B outsourcing facilities — registered with FDA under section 503B (FDA list, updated September 30, 2026)
- Hybrid pharmacies — dispensing both compounded and commercial drugs; must segregate compounding operations to PCAB standards
- Hospital pharmacy departments — compounding sterile preparations under USP 797 for inpatient use
- Oncology pharmacies — handling hazardous drugs under USP 800
- Specialty pharmacies — adding compounding capabilities to existing accreditation structures (URAC, ACHC, NABP)
USP Chapters 795, 797, and 800: What Each Requires
All three USP chapters simultaneously achieved final enforceable status on November 1, 2023. PCAB accreditation is built around demonstrating compliance with all three chapters as an integrated framework.
USP Chapter 795: Non-Sterile Compounding
USP 795 governs non-sterile preparations — creams, ointments, capsules, oral liquids, and similar dosage forms. The November 2023 final version introduced a water activity metric and stricter beyond-use date (BUD) defaults. Master Formulation Records must now document stability data meeting the new water activity standards. Organizations that relied on legacy BUD tables from pre-2023 guidance must review and update every affected formulation.
USP Chapter 797: Sterile Compounding
The 2023 final version replaced the former risk-level framework (low/medium/high) with a Category 1/2/3 BUD continuum tied to environmental control level. Key new requirements include:
- Formal Designated Person (DP) designation with documented responsibilities
- Semi-annual gloved fingertip and thumb sampling for all sterile compounding personnel
- Media fill testing documentation before personnel may manipulate patient drugs
- Environmental monitoring at frequencies tied to Category classification
- Shipping system validation — scientifically validated packaging for all product transit
USP Chapter 800: Hazardous Drug Handling
USP 800 governs the receipt, storage, compounding, dispensing, and disposal of hazardous drugs. It applies to any pharmacy that handles drugs on the NIOSH hazardous drug list — including many oncology, hormonal, and antiviral compounds commonly compounded for specialty uses. Key requirements include containment ventilated enclosures, specific gowning protocols, negative pressure areas, and deactivation/decontamination procedures.
The 503A vs. 503B Distinction
The Drug Quality and Security Act (DQSA, 2013) bifurcated the compounding industry into two tracks. 503A pharmacies compound patient-specific prescriptions and are regulated primarily by state boards of pharmacy under USP standards. 503B outsourcing facilities register with FDA and compound for office stock without patient-specific prescriptions, subject to current Good Manufacturing Practice (cGMP) requirements. IHS serves both tracks — with distinct consulting approaches for each regulatory framework.
The Current Regulatory Environment: Why Now Matters
Regulatory changes in 2025 and 2026 include:
State Board Enforcement Wave
Each state is reaching its own USP enforcement deadline on a rolling basis. Kentucky began active enforcement of revised USP 795/797/800 on January 1, 2026. Ohio extended its grace period through February 28, 2027. Organizations in pre-enforcement states should not wait for their deadline to begin preparation.
GLP-1 Regulatory Transition
The FDA's enforcement discretion for 503A pharmacies compounding semaglutide products terminated in April 2025, and for 503B facilities in May 2025. Pharmacies that built operations around GLP-1 compounding must now either exit this segment or navigate the formal prior authorization pathway.
Nonresident Licensure Requirements
Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure. California charges an $8,500 nonresident sterile compounding pharmacy license fee (California Board of Pharmacy). For multi-state operations, PCAB accreditation is not optional — it is a state licensure prerequisite in key markets.
The PCAB Accreditation Process: Phase by Phase
IHS plans for 7 to 8 months from the start of an engagement when baseline state inspections are complete, and 12 to 18 months for a full build from a non-compliant state. Here is how IHS structures the engagement.
Comprehensive Gap Assessment (Weeks 1–2)
IHS reviews your current clinical practices, physical environment, and documentation history against the finalized USP 795, 797, and 800 standards. The gap report is the foundation for the entire engagement timeline and internal resource plan.
Policy and Procedure (SOP) Development (Weeks 3–14)
The most time-intensive phase. IHS distributes customized policy chapters over 12 weeks, allowing pharmacy staff to digest, implement, and demonstrate compliance with one complex chapter before moving to the next. Key SOP domains include: cleanroom maintenance, environmental excursions, garbing sequences, hand hygiene, equipment calibration, shipping validation, Designated Person responsibilities, and hazardous drug handling.
Mock Survey and Remediation (Weeks 15–18)
IHS conducts a rigorous simulated audit including real-time observation of aseptic techniques, environmental monitoring log scrutiny, and staff competency testing. Gloved fingertip sampling and media fill documentation are verified against USP 797 requirements. IHS develops a remediation plan for the gaps the mock survey identifies.
Application and Document Submission (Week 19)
Your organization submits the formal application to ACHC with all required legal documentation and the comprehensive Preliminary Evidence Report. IHS prepares your submission and anticipates common documentation deficiencies before they trigger ACHC requests for information; your organization submits it to ACHC.
Formal On-Site Survey (Months 5–8)
ACHC's formal binding evaluation — which can be unannounced. IHS prepares your team for every element of surveyor assessment: aseptic technique observation, personnel record review, equipment calibration log audit, and environmental monitoring documentation.
Internal Staffing Requirements
External consulting does not replace internal staff commitment. PCAB preparation requires dedicated internal resources.
- Designated Person — 1.0 FTE for quality program oversight (legally required under new USP frameworks)
- Pharmacist-in-Charge — 0.5 FTE for documentation oversight during preparation
- All compounding staff — participation in competency demonstrations, media fill testing, and gloved fingertip sampling
PCAB Accreditation Cost and Timeline
PCAB/ACHC does not publish a universal rate card. Organizations request customized quotes through ACHC's Customer Central portal. Ask ACHC whether Alliance for Pharmacy Compounding (APC) membership discounts apply to base PCAB accreditation fees.
ACHC/PCAB Direct Fees
- Base PCAB accreditation fee: set by ACHC; request a current quote
- APC member discount: ask ACHC whether one applies
- Accreditation cycle: 36 months; renewal must begin 9 months before expiration
- Annual maintenance fee: None — costs consolidated into triennial survey
State Licensure Fees (Select States)
- California nonresident sterile compounding pharmacy license: $8,500 (California Board of Pharmacy)
IHS Consulting Fees
Engagement fees are customized based on your organization's complexity and timeline. Contact us for a tailored proposal.
PCAB Survey Areas to Prepare
IHS reviews the following areas with each pharmacy before survey.
Equipment Calibration and Maintenance
Failure to adequately clean, maintain, or keep rigorous calibration logs for sensitive compounding equipment. IHS implements comprehensive equipment log templates with electronic alert triggers for calibration due dates.
Safe Storage, Labeling, and Handling
Failure to continuously monitor, maintain, and document appropriate environmental metrics — temperature, humidity, pressure differentials — within the pharmacy. IHS establishes continuous monitoring systems with documented excursion response protocols.
Shipping System Validation
Pharmacies failing to use scientifically validated shipping materials guaranteeing appropriate temperature and sanitation during transit. IHS builds shipping validation packages that satisfy USP and PCAB requirements for every product category shipped.
Designated Person Designation
Failure to formally appoint, document, and define the responsibilities of a Designated Person as required under the new USP frameworks. IHS drafts the formal DP designation documentation and role charter required by both USP 797 and ACHC standards.
Personnel Training and Competency
Failure to maintain continuous documented training logs for staff engaged in complex compounding procedures. IHS builds the full competency assessment framework: initial training, semi-annual reassessment, and direct observation documentation for each procedure type.
Gloved Fingertip and Thumb Sampling Gaps
Total absence or lapsed documentation of required initial and ongoing semi-annual gloved fingertip sampling. This is a USP 797 requirement. IHS establishes the sampling schedule, documentation format, and remediation protocol for positive results.
Media Fill Testing Gaps
Missing documentation that personnel passed mandatory aseptic media fill challenges before manipulating actual patient drugs. IHS coordinates media fill testing events and builds the records package required for ongoing PCAB compliance.
Why Choose IHS for PCAB Accreditation and USP Compliance Consulting
Thomas G. Goddard, JD, PhD, personally leads IHS's pharmacy accreditation engagements. IHS offers:
- Integrated coverage: IHS provides integrated consulting covering the full compliance lifecycle — gap assessment, SOP development, mock survey, inspection defense, and post-survey remediation.
- Regulatory interplay expertise: IHS understands the interplay between PCAB, state board enforcement timelines, and FDA regulatory posture. This is critical for multi-state operations and 503B facilities navigating dual state/federal oversight.
- State enforcement timeline knowledge: Kentucky enforcing January 2026. Ohio enforcing February 2027. IHS provides state-specific transition planning that accounts for your state's actual enforcement calendar — not a generic national timeline.
- 503A and 503B expertise: IHS serves both regulatory tracks. For 503A pharmacies, the focus is PCAB accreditation and state board compliance. For 503B facilities, IHS provides cGMP consulting, FDA inspection preparation, and Form 483 response support.
- GLP-1 transition counsel: IHS helps 503A pharmacies navigate the post-enforcement-discretion regulatory landscape for semaglutide and tirzepatide.
Frequently Asked Questions
See our complete PCAB Accreditation and USP Compliance FAQ for 15+ detailed answers.
What changed with the revised USP Chapter 797 effective November 2023?
The 2023 final version replaced the old risk-level framework (low/medium/high BUD) with a Category 1/2/3 BUD continuum tied to environmental control level. New requirements include: formal Designated Person designation, semi-annual gloved fingertip sampling, media fill testing documentation, category-specific environmental monitoring frequencies, and shipping system validation.
Does PCAB accreditation satisfy state board of pharmacy USP compliance requirements?
PCAB accreditation demonstrates rigorous compliance with USP 795, 797, and 800 through independent third-party verification. However, state board requirements and PCAB standards are not legally identical. IHS helps organizations understand their specific state board requirements and how PCAB accreditation status affects their state compliance posture.
What is the difference between PCAB and NABP VPP?
PCAB focuses specifically on compounding pharmacy quality and is administered through ACHC. NABP's Verified Pharmacy Program (VPP) is a broader pharmacy accreditation covering dispensing, operations, and patient safety. See our full PCAB vs. NABP VPP comparison.
Which states require PCAB accreditation for nonresident compounding pharmacy licensure?
Washington and Ohio currently require verifiable PCAB accreditation as a condition of nonresident compounding pharmacy licensure. IHS monitors state board developments and provides current state-specific guidance in every engagement.
Ready to Start Your PCAB Accreditation Preparation?
Schedule a no-obligation gap assessment with Thomas G. Goddard, JD, PhD. IHS will assess your current compliance posture against USP 795, 797, and 800 requirements and give you a clear phased roadmap to PCAB accreditation.